We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma.
- Authors
Younes, A; Sarris, A; Melnyk, A; Romaguera, J; McLaughlin, P; Swan, F; Rodriguez, M A; Hagemeister, F; Moore, D; North, L
- Abstract
Paclitaxel (Taxol; Bristol-Myers Squibb Co, Princeton, NJ) is a novel antimicrotubule agent with anti-tumor activity against ovarian and breast carcinomas. Its activity when administered as a 3-hour intravenous infusion in patients with relapsed non-Hodgkin's lymphoma (NHL) has not been studied.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Vol 13, Issue 3, p583
- ISSN
0732-183X
- Publication type
Journal Article
- DOI
10.1200/JCO.1995.13.3.583